⚠ APLS is no longer actively traded. Data shown reflects verified historical relationships.
Supply Chain Intelligence

Apellis Pharmaceuticals, Inc. Supply Chain

APLS supply chain intelligence for Apellis Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

APLS ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

2Suppliers
1Customers
3Debt Items
8Related Chains

Apellis Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
CAPPED-CALL-COUNTERPARTIES CAPPED-CALL-COUNTERPARTIES 92% On May 14, 2026, the Company entered into unwind agreements with each Capped Call Counterparty pursuant to which, in the aggregate, all Capped Call Transactions were terminated in exchange for an imm…
LCTX Lineage Cell Therapeutics, Inc. 72% Reciprocal relationship from LCTX graph: or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by fed…

Apellis Pharmaceuticals, Inc. Customers

TickerNameConfidenceEvidence
LCTX Lineage Cell Therapeutics, Inc. 72% Reciprocal relationship from LCTX graph: velopment laboratories and a cGMP manufacturing facility, is designed and equipped to enable simultaneous cGMP processes and to produce a range of cell therap…

Apellis Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
APLS-DEBT-7793 Warrants outstanding: 430160 90% xbrl warrant detail from xbrl 2018-12-31.
APLS-DEBT-7794 Xbrl Convertible 90% xbrl convertible detail from xbrl 2022-12-31.
APLS-DEBT Debt stack $475.8M 90% Market cache reports total debt of $475.8M.

Apellis Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Apellis Pharmaceuticals, Inc..

Apellis Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
APLS-OWNER-MORGAN-STANLEY MORGAN STANLEY 90% 13F overlay lists MORGAN STANLEY as top holder; 330 tracked holders.

Apellis Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
LCTX Lineage Cell Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
NVO Novo Nordisk A/S 50.00 2
EISAI EISAI 50.00 2
IMDX Insight Molecular Diagnostics Inc. 50.00 2
GERN Geron Corporation 50.00 2
UCB United Community Banks, Inc. 50.00 2
BIIB Biogen Inc. 36.29 1 ['spend']
SUPN Supernus Pharmaceuticals, Inc. 14.78 2
View APLS supply chain intel →

Explore the full interactive supply chain map for Apellis Pharmaceuticals, Inc..

Open APLS supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map